2026-10-06T18:22:04Z
https://api.figshare.com/v2/oai
oai:figshare.com:article/34032348
2026-09-30T12:41:35Z
category_352
category_353
category_354
category_46
category_1329
category_725
category_696
category_346
category_347
category_348
category_349
category_350
category_351
portal_316
item_type_1
month_year_09_2026
Image_3_Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2.tif
Peng Yu (48605)
Jingping Ran (18109852)
Ruiqi Yang (4432951)
Hang Zhu (303107)
Song Lu (455448)
Yuzhang Wu (143824)
Tingting Zhao (1295883)
Tianchen Xiong (11920957)
Transplantation Immunology
Tumour Immunology
Immunology not elsewhere classified
Immunology
Veterinary Immunology
Animal Immunology
Genetic Immunology
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
Autoimmunity
Cellular Immunology
Humoural Immunology and Immunochemistry
Immunogenetics (incl. Genetic Immunology)
Innate Immunity
SARS-CoV-2
COVID-19
Omicron
neutralizing antibody
beacon
Introduction<p>The emergence of SARS-CoV-2 Omicron subvariants has presented a significant challenge to global health, as these variants show resistance to most antibodies developed early in the pandemic. Therapeutic antibodies with potent efficacy to the Omicron variants are urgently demanded.</p>Methods<p>Utilizing the rapid antibody discovery platform, Berkeley Lights Beacon, we isolated two monoclonal neutralizing antibodies, 2173-A6 and 3462-A4. These antibodies were isolated from individuals who recently recovered from Omicron infections.</p>Results<p>Both antibodies, 2173-A6 and 3462-A4, demonstrated high affinity for the RBD and effectively neutralized pseudoviruses from various Omicron lineages, including BA.4/5, XBB.1.16, XBB.1.5, and EG.5.1. This neutralization was achieved through binding to identical or overlapping epitopes.</p>Discussion<p>The use of the Beacon platform enabled the rapid isolation and identification of effective neutralizing antibodies within less than 10 days. This process significantly accelerates the development of novel therapeutic antibodies, potentially reducing the time required to respond to unknown infectious diseases in the future.</p>
2026-09-30T12:41:35Z
Image
Figure
10.3389/fimmu.2024.1374913.s003
https://figshare.com/articles/figure/Image_3_Rapid_isolation_of_pan-neutralizing_antibodies_against_Omicron_variants_from_convalescent_individuals_infected_with_SARS-CoV-2_tif/34032348
CC BY 4.0